We are international

Report from the Inaugural IMF - China Myeloma Symposium
October 20, 2007 in Beijing, China.
The successful Beijing Symposium is the latest in the IMF's long history of holding international symposiums to form collaborations with doctors and researchers around the world.

The International Myeloma Foundation held the Inaugural IMF - China Myeloma Symposium—Advances in Diagnosis and Treatment on October 20, 2007 in Beijing, China.

Faculty from left to right - Dr. Chen, Dr. Jagganath, Dr. Boccadoro,
Faculty from left to right - Dr. Chen, Dr. Jagganath, Dr. Boccadoro,
Dr. Durie, Dr. Huang, and Dr. Hou.

Dr. Brian G.M. Durie, National Program Director for Multiple Myeloma and Related Disorders and Senior Advisor for Hematologic Malignancies at Aptium Oncology was the meeting Chair. IMF Scientific Advisors joining him as faculty were Dr. Mario Boccadoro Director of Hematology at the University of Torino, Italy and Dr. Sundar Jagannath, Chief of the Multiple Myeloma Program at St. Vincent's Comprehensive Cancer Center, New York City.

Also participating as faculty were

  • Dr. Wen-Ming Chen, Director of the Multiple Myeloma Research Center of Beijing. Dr. Chen has conducted preclinical and clinical studies on early diagnosis and treatment of multiple myeloma. His main focus includes chemotherapy and stem cell transplantation, immunotherapy, antiangiogenesis and treatment of bone disease.

  • Dr. Jian Hou, professor and Director of the Department of Hematology for Changzheng Hospital Shanghai. Dr. Hou specializes in diagnosis and treatment of hematological malignancies, including leukemia, lymphoma and multiple myeloma. His clinical research includes chemotherapy, stem cell transplantation, and targeted therapy. Dr. Hou's primary research focus is pathogenesis and novel targets of myeloma, in which he has more than 110 publications.

  • Dr. Xiao-Jun Huang, Chairman of the Chinese Hematological Medical Association and Director of the Hematology Department in Beijing People's Hospital. Dr. Huang specializes in translational and clinical research on stem cell transplantation. He conducted research on novel therapeutic agents in the treatment of hematological malignant diseases at Albert Einstein Cancer Center from 1997 to 1998.

The Symposium began with welcoming comments from Dr. Brian Durie and Susie Novis, who thanked the attendees for attending the symposium and their work in myeloma. She expressed the IMF's interest in continuing to collaborate with doctors throughout Asia to help patients and to work together to find a cure for this disease. She noted the IMF's long history of holding symposiums around the world to form collaborations with doctors and researchers and pointed out that it was in Singapore in 1993 that the IMF had held its first international symposium.

The day began with Dr. Durie's presentation—Myeloma 2007, which covered the biology of myeloma, etiology and epidemiology, staging and clinical applications for new technologies.

Next Dr. Wen-Ming Chen presented New Technologies in Diagnosis and Prognosis, focusing on genomics and proteomics, serum Free Light Chain Immunoassay, and biomarkers as treatment and prognostic factors.

Dr. Sundar Jagannath presented Current Approachs to Frontline Therapy. He broke up his talk into 6 modules:

  • Module 1 - Old Treatment Paradigm
  • Module 2 - Novel Agent Thalidomide
  • Module 3 - Novel Agent Bortezomib
  • Module 4 - Novel Agent Lenalidomide
  • Module 5 - Novel Agents +MP
  • Module 6 - New Treatment Paradigm.

His talk prompted many questions from the audience and led to an interesting discussion.

After a short break, the symposium continued with Dr. Jian Hou's presentation, Current Status of Multiple Myeloma: Perspective from China. Dr. Hou showed the incidence and features of myeloma in Chinese patients, the treatment modalities used, and what the future directions are for myeloma treatment in China.

Dr. Xiao-Jun Huang next presented the Experience with Novel Therapy in China. His talk covered the clinical application of Bortezomib in Chinese myeloma patients, and Bortezomib in refractory and relapsed patients, and then discussed what they have learned so far from this experience and what the future directions are in therapy for patients in China.

Susie Novis and myeloma patient, Xinchao Tong
Susie Novis and myeloma patient, Xinchao Tong

During lunch Susie Novis had the pleasure of meeting a patient who informed her that there is now a patient group in China, and he expressed interest in collaborating with the IMF to help patients in China.

The symposium resumed with Dr. Mario Boccadoro's presentation of the Role of High Dose Therapy and Transplantation in Myeloma. His talk focused on the current trends in high dose therapy, transplant in myeloma patients both with autologous transplantation as well as allogeneic transplantation: perfect match or mismatch of an allele.

Dr. Brian Durie gave the final presentation of the day with his talk on Current Clinical Research in Multiple Myeloma. He presented combination modalities of novel therapies, treatment of refractory and relapsed myeloma and ongoing clinical trials on Bortezomib.

Dr. Durie
Dr. Durie

The day ended with a panel discussion that included the entire faculty who spoke about how to improve therapeutic outcomes for multiple Myeloma patients and what the potential is for collaborations with Chinese investigators.

 related articles